DDInter1613 DDInter178
Rofecoxib is used for the treatment of osteoarthritis, rheumatoid arthritis, acute pain in adults, and primary dysmenorrhea, as well as acute treatment of migraine attacks with or without auras. Rofecoxib is a solid. This compound belongs to the stilbenes. These are organic compounds containing a 1,2-diphenylethylene moiety. Stilbenes (C6-C2-C6 ) are derived from the common phenylpropene (C6-C3) skeleton building block. The introduction of one or more hydroxyl groups to a phenyl ring lead to stilbenoids. Rofecoxib has a half-life of 17 hours and its mean oral bioavailability at therapeutically recommended doses of 125, 25, and 50 mg is approximately 93%. The proteins that rofecoxib target include elastin and prostaglandin G/H synthase 2
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Apixaban
Rofecoxib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lepirudin
Rofecoxib {u} may lead to a major life threatening interaction when taken with {v} Iohexol
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Apixaban
Rofecoxib may cause a moderate interaction that could exacerbate diseases when taken with Lepirudin
Rofecoxib may lead to a major life threatening interaction when taken with Iohexol